New treatment approach for glioblastoma using nanoimmunodrugs
Targeting tumor microenvironment by nanoimmunodrugs for glioma treatment
This study is exploring a new way to treat glioblastoma, a tough type of brain cancer, by using tiny medicines that can reach the tumor and boost the body's immune response to fight it better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10931507 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for glioblastoma, the most aggressive form of brain cancer, by targeting the tumor microenvironment and enhancing the immune response in the brain. The approach utilizes advanced nanomedicines designed to effectively cross the blood-brain barrier, allowing for better delivery of therapeutic agents directly to the tumor site. By understanding the interactions between specific proteins in the tumor environment and the local immune system, the research aims to create a more effective treatment strategy that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are seeking new treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in using nanotechnology and immunotherapy for cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Ljubimov, Alexander V — Cedars-Sinai Medical Center
- Study coordinator: Ljubimov, Alexander V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.